MMP11 and CD2 as novel prognostic factors in hormone receptor-negative, HER2-positive breast cancer
Autor: | Jeong Eon Lee, Haein Kim, Jinil Han, Joon Seok Choi, Sarah Park, Young Kee Shin, Yoon-La Choi, Jong Sun Choi, Byung-Ho Nam, Seok Jin Nam, Jun Young Choi, Se Kyung Lee, Young Deug Kim, Mi Jeong Kwon |
---|---|
Rok vydání: | 2016 |
Předmět: |
0301 basic medicine
Oncology Adult Cancer Research medicine.medical_specialty Multivariate analysis Receptor ErbB-2 CD2 Antigens Breast Neoplasms Disease-Free Survival Risk of distant metastasis 03 medical and health sciences 0302 clinical medicine Immune system Breast cancer Preclinical Study Matrix Metalloproteinase 11 Internal medicine medicine Biomarkers Tumor Humans skin and connective tissue diseases HER2-positive (HR−/HER2+) breast cancer Aged Cell Proliferation Aged 80 and over Univariate analysis Framingham Risk Score business.industry Hormone receptor-negative Cancer Middle Aged medicine.disease Prognosis Immunity Innate Gene Expression Regulation Neoplastic 030104 developmental biology Hormone receptor 030220 oncology & carcinogenesis Lymphatic Metastasis Proliferation-related genes (p-genes) Female business Prognostic model Immune response-related genes (i-genes) Hormone |
Zdroj: | Breast Cancer Research and Treatment |
ISSN: | 1573-7217 |
Popis: | Purpose More accurate prediction of patient outcome based on molecular subtype is required to identify patients who will benefit from specific treatments. Methods We selected novel 16 candidate prognostic genes, including 10 proliferation-related genes (p-genes) and 6 immune response-related genes (i-genes), from the gene list identified in our previous study. We then analyzed the association between their expression, measured by quantitative real-time reverse transcription-PCR in formalin-fixed, paraffin-embedded tissues, and clinical outcome in 819 breast cancer patients according to molecular subtype. Results The prognostic significance of clinical and gene variables varied according to the molecular subtype. Univariate analysis showed that positive lymph node status was significantly correlated with the increased risk of distant metastasis in all subtypes except the hormone receptor-negative, HER2-positive (HR−/HER2+) subtype. Most p-genes were significantly associated with poor prognosis in patients with the HR+/HER2− subtype, whereas i-genes correlated with a favorable outcome in patients with HR−/HER2+ breast cancer. In HR−/HER2+ breast cancer, four genes (three i-genes BTN3A2, CD2, and TRBC1 and the p-gene MMP11) were significantly associated with distant metastasis-free survival (DMFS). A new prognostic model for HR−/HER2+ breast cancer based on the expression of MMP11 and CD2 was developed and the DMFS for patients in the high-risk group according to our model was significantly lower than that for those in the low-risk group. Multivariate analyses revealed that our risk score is an independent prognostic factor for DMFS. Moreover, C-index showed that our risk score has a superior prognostic performance to traditional clinicopathological factors. Conclusions Our new prognostic model for HR−/HER2+ breast cancer provides more accurate information on the risk of distant metastasis than traditional clinical prognostic factors and may be used to identify patients with a good prognosis in this aggressive subtype of breast cancer. Electronic supplementary material The online version of this article (doi:10.1007/s10549-017-4234-4) contains supplementary material, which is available to authorized users. |
Databáze: | OpenAIRE |
Externí odkaz: |